BLK
63
3
VMC
66
3
YUM
62
4
PEG
57
2
TROW
61
2
AES
72
4
O
46
6
QRVO
40
4
JWN
73
-3
GME
88
-10
FLR
43
-3
MAT
45
-2
AMZN
66
-6
AIG
63
-2
PYPL
31
-2
SHW
64
2
MSFT
64
2
KHC
31
-2
CRM
59
4
AMG
55
3
BLK
63
3
VMC
66
3
YUM
62
4
PEG
57
2
TROW
61
2
AES
72
4
O
46
6
QRVO
40
4
JWN
73
-3
GME
88
-10
FLR
43
-3
MAT
45
-2
AMZN
66
-6
AIG
63
-2
PYPL
31
-2
SHW
64
2
MSFT
64
2
KHC
31
-2
CRM
59
4
AMG
55
3
Financhill
Back

Keros Therapeutics Quote, Financials, Valuation and Earnings

Sell
20

KROS
Keros Therapeutics

Last Price:
54.03
Seasonality Move:
-7.87%

7 Day Trial

ALL ACCESS PASS

$ 7

Keros Therapeutics Price Quote

$54.03
-0.37 (-0.68%)
(Updated: May 16, 2024 at 6:55 PM ET)

Keros Therapeutics Key Stats

Sell
20
Keros Therapeutics (KROS) is a Sell
Day range:
$53.24 - $54.88
52-week range:
$27.02 - $73.00
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
4.32%
Volume:
199K
Avg. volume:
281.9K
1-year change:
15.88%
Market cap:
$2B
Revenue:
$151K
EPS:
$-5.15

How Much Does Keros Therapeutics Make?

Data Unavailable

Is Keros Therapeutics Growing As A Company?

Data Unavailable

Keros Therapeutics Stock Price Performance

What Is Keros Therapeutics 52-Week High & Low?

Keros Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Keros Therapeutics?

Is Keros Therapeutics Cash Flow Positive?

  • What Is KROS Cash Flow From Operations?
    Cash flow from operations (TTM) is -$134.8M
  • What Is Keros Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $228.1M
  • What Is Keros Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$2.3M

Keros Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    KROS return on invested capital is -45.46%
  • What Is Keros Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -41.68%
  • What Is KROS Return On Equity?
    ROE is a measure of profitability and is -45.46%

Keros Therapeutics Earnings Date & Stock Price

Keros Therapeutics Competitors

  • Who Are Keros Therapeutics's Competitors?
    Below is a list of companies who compete with Keros Therapeutics or are related in some way:
    • iBio Inc (IBIO)
    • Morphic Holding Inc (MORF)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Palatin Technologies Inc (PTN)
    • Theriva Biologics Inc (TOVX)

Keros Therapeutics Dividend Yield

Data Unavailable

Keros Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 9.28%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 8
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 88.44
Upside from Last Price: 62.58%

Major Shareholders

  • How many KROS shares are owned by institutional investors?
    39.6M KROS shares are owned by institutional investors
  • How many KROS shares are owned by insiders?
    372.2K KROS shares are owned by insiders